Clancy Paul J Form 4 February 03, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

See Instruction 1(b).

(Last)

(C:+-)

Common

Stock

(Print or Type Responses)

1. Name and Address of Reporting Person * Clancy Paul J

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

(Middle)

BIOGEN IDEC INC. [BIIB]

3. Date of Earliest Transaction

(Check all applicable)

OMB

Number:

Expires:

response...

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

BIOGEN IDEC INC., 133 BOSTON

(Month/Day/Year) 02/01/2012

Director 10% Owner Other (specify X_ Officer (give title below)

POST ROAD

(Street)

(Ctota)

02/01/2012

(First)

Executive VP and CFO 6. Individual or Joint/Group Filing(Check

D

4. If Amendment, Date Original Filed(Month/Day/Year)

Applicable Line)

Person

X Form filed by One Reporting Person Form filed by More than One Reporting

WESTON, MA 02493

(City)	(State)	Tabl	e I - Non-D	erivative S	Securi	ties Acqu	ired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securitin(A) or Dis (Instr. 3, 4	sposed	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/01/2012		M(1)		A		34,168	D	
Common Stock	02/01/2012		M(1)	8,400	A	\$ 67.57	42,568	D	
Common Stock	02/01/2012		S <u>(1)</u>	13,000	D	\$ 120 (2) (3)	29,568	D	

8,400

D

\$ 120 21,168

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $S^{(1)}$

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of on Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 43.5	02/01/2012		M <u>(1)</u>	13,000	<u>(4)</u>	02/06/2014	Common Stock	13,000
Stock Option (Right to Buy)	\$ 67.57	02/01/2012		M <u>(1)</u>	8,400	(5)	02/17/2015	Common Stock	8,400

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Clancy Paul J BIOGEN IDEC INC. 133 BOSTON POST ROAD WESTON, MA 02493

Executive VP and CFO

Signatures

/s/ Aras Lapinskas, Attorney in Fact for Paul J. Clancy

02/03/2012

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- (2) This represents the weighted average price for shares sold at a range between \$120.00 (low) and \$120.01 (high).

Reporting Owners 2

Edgar Filing: Clancy Paul J - Form 4

- (3) Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
- (4) The stock option becomes exercisable in four(4) equal annual installments, commencing one year after the grant date of 02/06/04.
- (5) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/17/05.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.